Related Experiment Video
Updated: Aug 5, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
50.1K
Colonic motility adjustments in acute and chronic DSS-induced colitis
Paulo da Silva Watanabe1, Andreza Manzato Cavichioli1, Joana D'Arc de Lima Mendes1
1Department of Histology, State University of Londrina, Londrina, PR, Brazil.
Life Sciences
|March 29, 2023
Summary
Inflammatory bowel disease, specifically ulcerative colitis (UC), causes colon wall thickening, fibrosis, and altered neuron function, leading to colonic dysmotility. Stimulating tuft cells may help maintain colon health.
Area of Science:
- Gastroenterology
- Neuroscience
- Immunology
Background:
- Inflammatory bowel disease (IBD) involves recurrent gastrointestinal inflammation, impacting intestinal motility.
- The precise mechanisms driving motility changes in IBD, such as ulcerative colitis (UC), are not fully understood.
- Understanding these mechanisms is crucial for developing effective treatments.
Purpose of the Study:
- To investigate anatomical and functional changes in the colon during acute and chronic DSS-induced UC in mice.
- To correlate morphological alterations with changes in colonic motility patterns.
- To identify potential therapeutic targets for UC-related dysmotility.
Main Methods:
- Mice were divided into control and DSS-exposed groups (acute and chronic UC models).
- Colonic tissues were analyzed using histology and immunofluorescence.
- Colon manometry was employed to assess functional motility changes.
Main Results:
- DSS-induced UC caused colonic wall thickening, fibrosis, and reduced tuft and goblet cells.
- While neuronal death was not observed, changes in myenteric neuron chemical coding occurred.
- These morphological changes resulted in altered colonic contractions, motility patterns, and gastrointestinal transit time, leading to dysmotility.
Conclusions:
- Progressive UC pathology induces structural and neuroanatomical changes in the colon.
- Damage to cholinergic neurons contributes significantly to colonic dysmotility.
- Variations in motility patterns across different colon regions characterize UC-induced dysmotility.
Related Concept Videos
01:20Drugs Affecting GI Tract Motility: Other Laxatives
314
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
314
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
267
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
267
01:17Drugs for Treatment of Diarrhea-Predominant IBS
238
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
238
01:21Inflammatory Bowel Disease V: Surgical Management
179
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
179
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
333
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
333
01:20Gastrointestinal Motility Disorders
491
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
491